Femasys logs first commercial use of FemaSeed Complete in OB/GYN offices
Femasys has recorded the first commercial, revenue-generating use of its FemaSeed Complete fertility system within an OB/GYN practice, marking an early commercial milestone for the NASDAQ-listed medical device company. The system combines FemaSeed intratubal insemination (ITI) with FemSperm, an in-office sperm preparation product, allowing gynaecologists to deliver a complete fertility treatment without referring patients to specialist fertility centres.
The procedure was performed by Dr Finazzo of Downriver OBGYN in Trenton, Michigan, and represents the first deployment of the full FemaSeed Complete workflow in a routine outpatient setting. Femasys said the system is designed for a single in-office visit, eliminating the need for external laboratory processing and the specialist referrals that typically accompany conventional fertility treatment pathways.
Addressing the access gap
Femasys is framing FemaSeed Complete as a structural fix for what it describes as a pronounced gap in US fertility care. The company cites estimates suggesting infertility affects approximately ten million women in the United States, yet fewer than 1% receive treatment at dedicated fertility centres. Recent CDC data showing US fertility rates fell to record lows in 2025 adds further urgency to the company's commercial narrative.
Kathy Lee-Sepsick, founder and chief executive of Femasys, said the commercial launch follows FDA clearance of FemaSeed — described by the company as having come ahead of schedule — and subsequent clinical validation at infertility centres. "Following FemaSeed's earlier than expected US FDA clearance and subsequent clinical validation in infertility centers, the availability of FemSperm now expands our capabilities to include in-office sperm preparation, enabling a complete solution in the OBGYN setting," she said.
Published clinical data cited by the company indicate FemaSeed achieved more than double the pregnancy rate of traditional intrauterine insemination (IUI), with a comparable safety profile. That comparison carries weight commercially: IUI is the most widely used first-line assisted reproduction procedure, and a superior pregnancy rate — if borne out at scale — would give OB/GYNs a clinically credible reason to keep fertility workups in-house rather than refer onward.
Market context and competitive landscape
The OB/GYN-based fertility market is nascent but attracting attention as IVF costs and access constraints become a more prominent political and healthcare issue. IVF remains the dominant intervention for moderate-to-severe infertility and commands high reimbursement where covered, but the procedural burden, cost — typically £10,000–£15,000 per cycle in the US without insurance — and geographical concentration of specialist clinics leave a large untreated population. Femasys is positioning FemaSeed Complete squarely in this gap, targeting the majority of women who already have an established OB/GYN relationship but have not yet sought specialist fertility input.
No comparable integrated ITI-plus-sperm-preparation commercial system appears to have achieved regulatory clearance and commercial availability in this channel in the United States, though Femasys has not made an explicit first-in-class claim in its commercial materials. The company's broader portfolio — which also includes FemVue, a companion fallopian tube diagnostic, and FemBloc, a non-surgical permanent contraception device currently under FDA review in the FINALE pivotal trial — suggests a strategy of owning a suite of in-office gynaecological procedure tools across the reproductive lifecycle.
For investors, the key near-term question is how quickly adoption scales beyond early-adopter OB/GYN practices. Femasys launched at the American College of Obstetricians and Gynaecologists (ACOG) annual meeting and said it is "focused on rapidly advancing this new model of care," but provided no commercial targets, physician pipeline numbers, or revenue guidance in the release.